ZS Pharma prices IPO at $18, above the range


Shutterstock photo

ZS Pharma, a late-stage biotech developing a treatment for excess potassium (hyperkalemia), raised $107 million by offering 5.9 million shares (vs. 5 million originally planned) at $18, above the $15 to $17 range. ZS Pharma will list on the NASDAQ under the symbol ZSPH. J.P. Morgan and Credit Suisse acted as joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com